TD Cowen analyst Marc Frahm lowered the firm’s price target on Incyte to $88 from $92 and keeps an Outperform rating on the shares. The firm said they reported solid Opzelura demand growth which led to a modest beat. They believe Jakafi guidance may prove conservative in light of a potential tailwind to volumes from Medicare Part D changes in 2024-25.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on INCY: